Literature DB >> 2695126

Tyramine and irreversible monoamine oxidase inhibitors in clinical practice.

A J Cooper1.   

Abstract

The cheese reaction following use of the irreversible monoamine oxidase inhibitors (MAOIs) began to be reported in the UK with increasing frequency from about 1961. By 1965, the underlying mechanism (tyramine-provoked hypertension) had been essentially elucidated. Thereafter, this potentially severe side-effect could have been largely avoided by the use of fairly simple dietary precautions. Unfortunately, suspicion and fear burgeoned, and both the seriousness and the frequency of risk were dramatically inflated. This was a major factor in the subsequent general disuse of the irreversible MAOIs. Second-generation MAOIs which are selective for monoamine oxidase-A and B are now being synthesised and may eliminate the eventuality of hypertension without special dietary precautions.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2695126

Source DB:  PubMed          Journal:  Br J Psychiatry Suppl        ISSN: 0960-5371


  7 in total

1.  The role of monoamine oxidase inhibitors in current psychiatric practice.

Authors:  Jess G Fiedorowicz; Karen L Swartz
Journal:  J Psychiatr Pract       Date:  2004-07       Impact factor: 1.325

2.  The selegiline transdermal system (emsam): a therapeutic option for the treatment of major depressive disorder.

Authors:  Lois Jessen; Lawrence J Kovalick; Albert J Azzaro
Journal:  P T       Date:  2008-04

Review 3.  Treating mood disorders during pregnancy: safety considerations.

Authors:  Malin Eberhard-Gran; Anne Eskild; Stein Opjordsmoen
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 4.  Monoamine oxidase inhibitors. An update on drug interactions.

Authors:  M G Livingston; H M Livingston
Journal:  Drug Saf       Date:  1996-04       Impact factor: 5.606

Review 5.  International Union of Pharmacology. LXXII. Recommendations for trace amine receptor nomenclature.

Authors:  Janet J Maguire; William A E Parker; Steven M Foord; Tom I Bonner; Richard R Neubig; Anthony P Davenport
Journal:  Pharmacol Rev       Date:  2009-03       Impact factor: 25.468

Review 6.  EMSAM (deprenyl patch): how a promising antidepressant was underutilized.

Authors:  Gregory M Asnis; Margaret A Henderson
Journal:  Neuropsychiatr Dis Treat       Date:  2014-10-06       Impact factor: 2.570

7.  Transdermal selegiline for the treatment of major depressive disorder.

Authors:  Kelly C Lee; Jack J Chen
Journal:  Neuropsychiatr Dis Treat       Date:  2007       Impact factor: 2.570

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.